The protesters are calling on the San Diego City Council to give residents more input on the placement of cell towers in their community.

Pfizer’s Adcetris combination regimen gets US FDA approval to treat relapsed/refractory diffuse large B-cell lymphoma: New York Friday, February 14, 2025, 11:00 Hrs [IST] Pfizer ...

Meet the jumbo phage. Scientists believe they’ve cracked the code on how its ‘secret handshakes’ act as a shield against the ...

SOUTH SAN FRANCISCO - Allogene Therapeutics, Inc. (NASDAQ:ALLO), a biotechnology firm specializing in allogeneic CAR T ...

Allogene Therapeutics (ALLO) announced the publication of data from its Phase 1 ALPHA and ALPHA2 clinical studies of cemacabtagene ...

The lab of Dr. Mark Magnuson, Louise B. McGavock Professor and professor of molecular physiology and biophysics at Vanderbilt ...

Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

Leaked data showed that Pfizer’s mevrometostat has strong therapeutic potential in metastatic castration-resistant prostate ...

Susan Williams,seated center, a patient at the John B. Amos Cancer Center in Columbus, Georgia, is receiving a new cancer ...

MaxCyte's technology will support TG Therapeutics' efforts to develop a CD19 CAR T cell therapy program for autoimmune diseases.

The FDA has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and rituximab to treat patients with relapsed/refractory LBCL after 2 or more lines of systemic therapy who ...

The FIRCE-1 trial investigating the CAR T-cell therapy firi-cel in relapsed/refractory large B-cell lymphoma has been ...